PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
REGULATORY
MHLW Panel OKs Celgene’s Apremilast, 2 Other NMEs
A key advisory committee of the Ministry of Health, Labor and Welfare (MHLW) recommended approval for three new molecular entities (NMEs) including Celgene’s apremilast on November 24. The Pharmaceutical Affairs and Food Sanitation Council’s Second Committee on Drugs, a de-facto…
To read the full story
Related Article
- MHLW OKs Tecfidera, Otezla, Other Drugs
December 20, 2016
- Public Knowledge-Based Application Filed for Tamiflu’s New Pediatric Dosage
December 19, 2016
- HIV Med Descovy Approved in Japan
December 12, 2016
- Keytruda Clears MHLW Panel for Both 1st-Line, 2nd-Line NSCLC
November 25, 2016
REGULATORY
- PMDA Says IT Systems Could Go Offline Without Warning
October 27, 2026
- AbbVie’s Fast-Acting Botulinum Toxin Boey Wins Japan Panel Backing
October 27, 2026
- LDP Lawmakers Renew Push for Routine HPV Shots for Males by April 2027
October 27, 2026
- MHLW to Discuss Faster MCM Approvals during Health Emergencies
October 26, 2026
- Foreign Price Adjustment Rule a Key Issue in Japan’s MFN Response: Official
October 26, 2026
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…